Literature

Scientific publications

Here you can find key scientific publications from Dr. Andersson's research group as well as important publications from other research groups. The publications have been chosen due to their significant implications they have for the aim and focus of WntResearch to develop anti-metastatic treatments for cancer patients.

 


 

Giacomo Canesin, Susan Evans-Axelsson, Rebecka Hellsten, Nicholas Don-Doncow, Tommy Andersson, Anders Bjartell. Lund University, Malmö, Sweden

Targeting Wnt5a and STAT3 pathways for the treatment of prostate cancer
AACR, 18-22 April 2015

[Read more]

 

Linnskog R, Axelsson L, Jönsson G and Andersson T.

Interleukin-6 drives melanoma cell motility through p38a-MAPK-dependent up-regulation of WNT5A expression.
Molecular Oncology in press, 2014.

[Read more]

  

Ekström Ej, Bergenfelz C, Von Bulow V, Serifler F, Carlemalm E, Jönsson G, Andersson T and Leandersson K.

WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.
Molecular Cancer 13:88; pages 1-15, 2014

[Read more]

 

Cheng R, Sun B, Liu Z, Zhao X, Qi L, Li Y, Gu Q.

Wnt5a Suppresses Colon Cancer by Inhibiting Cell Proliferation and Epithelial-Mesenchymal Transition.

[Read more]

 

Jiang W, Crossman Dk, Mitchell Eh, Sohn P, Crowley Mr, Serra R.

WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells.

[Read more]

 

Niu Cc, Zhao C, Zhang Xl, Pan J, Zhao C, Wu Wr, Li Zq, Liu T, Yang Z, Si Wk.

Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.

[Read more]

 

Trifa F, Karray-Chouayekh S, Jmal E, Jmaa Zb, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R.

Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients.

[Read more]

 

Sherwood V, Chaurasiya Sk, Ekström Ej, Guilmain W, Qing L, Koeck T, Brown K, Hansson K, Agnarsdottir M, Bergqvist M, Jirström K, Ponten F, James P, Andersson T.

WNT5A-mediated b-catenin-independent signaling is a novel regulator of cancer cell metabolism.

[Read more]

 

Prasad Cp, Chaurasiya Sk, Axelsson L, Andersson T.

WNT-5A triggers Cdc42 activation leading to an ERK12 dependent decrease in MMP9 activity and invasive migration of breast cancer cells.

[Read more].

 

Sand-Dejmek J, Ehrnström R, Berglund P, Andersson T, Ryden L.

The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.

[Read more].

 

Khaja Ass, Egevad L, Helczynski L, Wiklund P, Andersson T, Bjartell A.

Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer.

Cancer Medicine 1(1):96-104, 2012.

[Read more]

 

Syed Khaja As, Helczynski L, Edsjö A, Ehrnström R, Lindgren A, Ulmert D, Andersson T, Bjartell A.

Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome.

[Read more].

 

Bitler Bg, Nicodemus Jp, Li H, Cai Q, Wu H, Hua X, Li T, Birrer Mj, Godwin Ak, Cairns P, Zhang R.

Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.

[Read more].

 

Ekström Ej, Sherwood V, Andersson T.

Methylation and loss of secreted frizzled-related protein 3 enhances melanoma cell migration and invasion.

[Read more].

 

Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, Vijayakumar S, Economides An, Aaronson Sa.

Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated corecptors.

[Read more].

 

Weeraratma At, Jpibem R, P'connell Mp, Becker Jc.

Lack of Wnt5A expression in Merkel cell carcinoma.

[Read more].

 

Peng L, Ye L, Dong G, Ren Lb, Wang Cl, Xu P, Zhou Xd.

WNT5A inhibits human dental papilla cell proliferation and migration.

[Read more].

 

Martin V, Valencia A, Agirre X, Cervera J, San Jose-Eneriz E, Vilas-Zornoza A, Rodriguez-Otero P, Sanz Ma, Herrera C, Torres A, Prosper F, Roman-Gomez J.

Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia.

[Read more].

 

O'connell Mp, Fiori Jl, Xu M, Carter Ad, Frank Bp, Camilli Tc, French Ad, Dissanayake Sk, Indig Fe, Bernier M, Taub Dd, Hewitt Sm, Weeraratna At.

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma

[Read more].

 

Yuzugullu  H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali Kc, Atebey N, Ozturk M.

Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellulara carcinoma cells

[Read more].

 

O'connell Mp, Weeraratna At.

Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

[Read more].

 

O'connell Mp, Fiori Jl, Kershner Ek, Frank Bp, Indig Fe, Taub Dd, Hoek Ks, Weeraratna At.

HSPG modulation of signal transduction in metastatic melanoma.

[Read more].

 

Hansen C, Howlin J, Tengholm A, Dyachok O, Vogel Wf, Nairn Ac, Greengard P, Andersson T.

Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner.

[Read more].

 

Medrek C, Landberg G, Andersson T, Leandersson K.

Wnt-5a-CKIa signaling promotes b-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells.

[Read more].

 

O'connell Mp, Fiori Jl, Baugher Km, Indig Fe, French Ad, Camilli Tc, Frank Bp, Earley R, Hoek Ks, Hasskamp Jh, Elias Eg, Taub Dd, Bernier M, Weeraratna At.

Wnt5A activates the calpain-mediated cleavage of filamin A.J

[Read more].

 

Chien Aj, Moore Ec, Lonsdorf As, Kulikauskas Rm, Gould Rothberg B, Berger Aj, Major Mb, Hwang St, Rimm Dl, Moon Rt.

Activated Wnt/b-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.

[Read more].

 

Dissanayake Sk, Olkhanud Pb, O'connell Mp, Carter A, French Ad, Camilli Tc, Emeche Cd, Hewitt Kj, Rosenthal Dt, Leotlela Pd, Wade Ms, Yang Sw, Brant L, Nickoloff Bj, Messina Jl, Biragyn A, Hoek Ks, Taub Dd, Longo Dl, Sondak Vk, Hewitt Sm, Weeraratna At:

Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

[Read more].

 

Säfholm A, Tuomela J, Rosenkvist J, Dejmek J, Härkönen P & Andersson T:

The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility.

[Read more].

 

Ying J, Li H, Yu J, Ng, Km, Poon Ff, Wong Sc, Chan At, Sung Jj & Tao Q:

WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/ -Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer.

[Read more].

 

Da Forno Pd, Pringle Jh, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox Ra, Fletcher A, Saldanha Gs.

WNT5A expression increases during melanoma progression and correlates with outcome.

[Read more].

 

Roarty K, Serra R.

Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth.

[Read more].

 

Ying J, Li H, Chen Yw, Srivastava G, Gao Z, & Tao Q.

WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor.

[Read more].

 

Leandersson K, Riesbeck K & Andersson T:

Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells.

[Read more].

 

Dejmek J, Säfholm A, Kamp-Nielsen C, Andersson T, & Leandersson K:

Wnt-5a/Ca2+ induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-CK1a signaling in human mammary epithelial cells. 

[Read more].

 

Säfholm A, Leandersson K, Dejmek J, Kamp-Nielsen C, Villoutreix B & Andersson T:

A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. 

[Read more].

 

Dejmek J, Dejmek A, Säfholm A, Sjölander A & Andersson T:

Wnt-5a protein expression in primary Dukes B colon cancer s identifies a subgroup of patients with good prognosis.

[Read more].

 

Blanc E, Roux Gl, Benard J, Raguenez G.

Low expression of Wnt-5a gene is associated with high-risk neuroblastoma.

[Read more].

 

Kremenevskaja N, Von Wasielewski R, Rao As, Schöfl C, Andersson T, Brabant G.

Wnt-5a has tumour suppressor activity in thyroid carcinoma.

[Read more].

 

Dejmek J, Leandersson K, Manjer J, Bjartell A, Emdin So, Vogel W, Landberg G, & Andersson T:

The Expression and Signaling Activity of Wnt-5a/DDR1 and Syk Play Distinct but Decisive Roles in Breast Cancer Patient Survival.

[Read more].

 

Liang H, Chen Q, Coles Ah, Anderson Sj, Pihan G, Bradley A, Gerstein R, Jurecic R & Jones Sn:

Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue

[Read more].

 

Weeraratna At, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M & Trent Jm: 

Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.

[Read more].         

  

Jönsson M, Dejmek J, Bendahl P-O & Andersson T:

Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas.  

[Read more].

 

Jönsson M & Andersson T:

Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells.  

[Read more].